date:Nov 08, 2013
Morinaga, the second largest dairy product company in Japan, has announced that the U.S. Food and Drug Administration (FDA) has issued Generally Recognized as Safe (GRAS) Letters of No Objection for Morinagas proprietary probiotic strain, Bifidobacterium breve M-16V for food applications and infant formulas.
The GRAS process is an FDA-recognised pathway that permits companies to have GRAS reviews carried out by independent panels of scientists, followed by GRAS determinations if an ingredient m